» Articles » PMID: 18984156

Nf1-dependent Tumors Require a Microenvironment Containing Nf1+/-- and C-kit-dependent Bone Marrow

Abstract

Interactions between tumorigenic cells and their surrounding microenvironment are critical for tumor progression yet remain incompletely understood. Germline mutations in the NF1 tumor suppressor gene cause neurofibromatosis type 1 (NF1), a common genetic disorder characterized by complex tumors called neurofibromas. Genetic studies indicate that biallelic loss of Nf1 is required in the tumorigenic cell of origin in the embryonic Schwann cell lineage. However, in the physiologic state, Schwann cell loss of heterozygosity is not sufficient for neurofibroma formation and Nf1 haploinsufficiency in at least one additional nonneoplastic lineage is required for tumor progression. Here, we establish that Nf1 heterozygosity of bone marrow-derived cells in the tumor microenvironment is sufficient to allow neurofibroma progression in the context of Schwann cell Nf1 deficiency. Further, genetic or pharmacologic attenuation of c-kit signaling in Nf1+/- hematopoietic cells diminishes neurofibroma initiation and progression. Finally, these studies implicate mast cells as critical mediators of tumor initiation.

Citing Articles

UBR5 in Tumor Biology: Exploring Mechanisms of Immune Regulation and Possible Therapeutic Implications in MPNST.

Odhiambo D, Fan S, Hirbe A Cancers (Basel). 2025; 17(2).

PMID: 39857943 PMC: 11764400. DOI: 10.3390/cancers17020161.


Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer.

Li C, Cordes A, Oliphant M, Quinn S, Thomas M, Selfors L Nat Genet. 2024; 56(12):2763-2775.

PMID: 39528827 DOI: 10.1038/s41588-024-01958-6.


Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance.

Pundavela J, Dinglasan S, Touvron M, Hummel S, Hu L, Rizvi T Sci Adv. 2024; 10(42):eado6342.

PMID: 39413183 PMC: 11482331. DOI: 10.1126/sciadv.ado6342.


Targeting the peripheral neural-tumour microenvironment for cancer therapy.

Yaniv D, Mattson B, Talbot S, Gleber-Netto F, Amit M Nat Rev Drug Discov. 2024; 23(10):780-796.

PMID: 39242781 DOI: 10.1038/s41573-024-01017-z.


The +/- Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation.

White E, Rhodes S Cancers (Basel). 2024; 16(5).

PMID: 38473354 PMC: 10930863. DOI: 10.3390/cancers16050994.


References
1.
Ingram D, Yang F, Travers J, Wenning M, Hiatt K, New S . Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med. 2000; 191(1):181-8. PMC: 2195790. DOI: 10.1084/jem.191.1.181. View

2.
Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

3.
Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K . Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10):737-44. PMC: 2852586. DOI: 10.1038/35036374. View

4.
Coussens L, Tinkle C, Hanahan D, Werb Z . MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000; 103(3):481-90. PMC: 2843102. DOI: 10.1016/s0092-8674(00)00139-2. View

5.
Ingram D, Hiatt K, King A, Fisher L, Shivakumar R, Derstine C . Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med. 2001; 194(1):57-69. PMC: 2193446. DOI: 10.1084/jem.194.1.57. View